Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Sweden
/
Pharmaceuticals & Biotech
Create a narrative
Swedish Orphan Biovitrum
OM:SOBI Community
1
Narratives
written by author
0
Comments
on narratives written by author
10
Fair Values set
on narratives written by author
Create a narrative
Swedish Orphan Biovitrum
Popular
Undervalued
Overvalued
Swedish Orphan Biovitrum
WA
Analyst Price Target
Consensus Narrative from 12 Analysts
Altuvoct And Beyfortus Launches Will Open Access To New Markets
Key Takeaways Expansion of hematology and immunology divisions, with new product launches, drives strong revenue growth and market positioning. Strategic partnerships and R&D pipeline innovations are crucial for accessing new markets and sustaining long-term earnings growth.
View narrative
SEK 366.77
FV
13.9% undervalued
intrinsic discount
9.96%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
23 days ago
author updated this narrative
Your Valuation for
SOBI
Swedish Orphan Biovitrum
Your Fair Value
SEK
Current Price
SEK 315.80
11.0% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-268m
41b
2015
2018
2021
2024
2025
2027
2030
Revenue SEK 40.7b
Earnings SEK 6.1b
Advanced
Set as Fair Value